INTEGRATED BIOPHARMA INC: operating cash flow
Operating cash flow for INTEGRATED BIOPHARMA INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All INTEGRATED BIOPHARMA INC financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-07-01 to 2025-06-30. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-07-01 | 2025-06-30 | 2,065,000 | USD | 2025-09-23 | 10-K · 0001437749-25-029711 |
| 2023-07-01 | 2024-06-30 | 943,000 | USD | 2025-09-23 | 10-K · 0001437749-25-029711 |
| 2022-07-01 | 2023-06-30 | 1,232,000 | USD | 2024-09-20 | 10-K · 0001437749-24-029768 |
| 2021-07-01 | 2022-06-30 | 4,091,000 | USD | 2023-09-15 | 10-K · 0001437749-23-026022 |
| 2020-07-01 | 2021-06-30 | 3,050,000 | USD | 2022-09-13 | 10-K · 0001437749-22-022334 |
| 2019-07-01 | 2020-06-30 | 1,339,000 | USD | 2021-09-02 | 10-K · 0001437749-21-021375 |
| 2018-07-01 | 2019-06-30 | 328,000 | USD | 2020-09-23 | 10-K · 0001437749-20-020123 |
| 2017-07-01 | 2018-06-30 | 1,168,000 | USD | 2019-08-29 | 10-K · 0001437749-19-017611 |
| 2016-07-01 | 2017-06-30 | 397,000 | USD | 2018-09-12 | 10-K · 0001437749-18-016922 |
| 2014-07-01 | 2015-06-30 | -113,000 | USD | 2015-09-04 | 10-K · 0001016504-15-000010 |
| 2013-07-01 | 2014-06-30 | 1,877,000 | USD | 2015-09-04 | 10-K · 0001016504-15-000010 |
| 2012-07-01 | 2013-06-30 | -1,438,000 | USD | 2014-09-08 | 10-K · 0001016504-14-000008 |
| 2011-07-01 | 2012-06-30 | -771,000 | USD | 2013-09-30 | 10-K · 0001016504-13-000011 |
| 2010-07-01 | 2011-06-30 | 392,000 | USD | 2012-10-15 | 10-K · 0001016504-12-000022 |
Related financial histories
- INTEGRATED BIOPHARMA INC: total assets
- INTEGRATED BIOPHARMA INC: total liabilities
- INTEGRATED BIOPHARMA INC: stockholders equity
- INTEGRATED BIOPHARMA INC: cash and cash equivalents
- INTEGRATED BIOPHARMA INC: net income or loss
- INTEGRATED BIOPHARMA INC: capital expenditure payments
- INTEGRATED BIOPHARMA INC: revenue
- INTEGRATED BIOPHARMA INC: financing cash flow
- INTEGRATED BIOPHARMA INC: investing cash flow
- INTEGRATED BIOPHARMA INC: retained earnings or deficit
- INTEGRATED BIOPHARMA INC: basic weighted-average shares
- INTEGRATED BIOPHARMA INC: diluted weighted-average shares
- INTEGRATED BIOPHARMA INC: basic earnings per share
- INTEGRATED BIOPHARMA INC: diluted earnings per share
- INTEGRATED BIOPHARMA INC: income tax expense or benefit
- INTEGRATED BIOPHARMA INC: net property, plant and equipment
- INTEGRATED BIOPHARMA INC: share-based compensation expense
- INTEGRATED BIOPHARMA INC: operating income or loss
- INTEGRATED BIOPHARMA INC: current assets
- INTEGRATED BIOPHARMA INC: interest expense
- INTEGRATED BIOPHARMA INC: current liabilities
- INTEGRATED BIOPHARMA INC: current accounts payable
- INTEGRATED BIOPHARMA INC: net finite-lived intangible assets
- INTEGRATED BIOPHARMA INC: net current accounts receivable
- INTEGRATED BIOPHARMA INC: net inventory
- INTEGRATED BIOPHARMA INC: gross profit
- INTEGRATED BIOPHARMA INC: selling, general and administrative expense
Inspect the source
- Entity
- INTEGRATED BIOPHARMA INC / CIK 0001016504
- Captured
- 2026-09-20T05:13:02.120Z
- SEC response SHA-256
f9ec590a908b38ef1a59595c204a1a8d2ad866020a5c8107d7a41fc708faf496
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001016504.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))